Validated UPLC-MS/MS method for quantification of fruquintinib in rat plasma and its application to pharmacokinetic study

References

• Xu RH, Li J, Bai Y, et al. Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study. J Hematol Oncol. 2017;10(1):22–30. doi:10.1186/s13045-016-0384-928103904
   PubMed Web of Science ®Google Scholar
• Cao J, Zhang J, Peng W, et al. A Phase I study of safety and pharmacokinetics of fruquintinib, a novel selective inhibitor of vascular endothelial growth factor receptor-1, −2, and −3 tyrosine kinases in Chinese patients with advanced solid tumors. Cancer Chemother Pharmacol. 2016;78(2):259–269. doi:10.1007/s00280-016-3069-827299749
   PubMed Web of Science ®Google Scholar
• Boere IA, Hamberg P, Sleijfer S. It takes two to tango: combinations of conventional cytotoxics with compounds targeting the vascular endothelial growth factor-vascular endothelial growth factor receptor pathway in patients with solid malignancies. Cancer Sci. 2010;101(1):7–15. doi:10.1111/j.1349-7006.2009.01369.x19860846
   PubMed Web of Science ®Google Scholar
• Veeravagu A, Hsu AR, Cai W, Hou LC, Tse VC, Chen X. Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as anti-angiogenic agents in cancer therapy. Recent Pat Anticancer Drug Discov. 2007;2(1):59–71.18221053
   PubMed Web of Science ®Google Scholar
• Sun Q, Zhou J, Zhang Z, et al. Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy. Cancer Biol Ther. 2014;15(12):1635–1645. doi:10.4161/15384047.2014.96408725482937
   PubMed Web of Science ®Google Scholar
• Zhou CC, Bai CX, Guan ZZ, et al. Safety and efficacy of first-line bevacizumab combination therapy in Chinese population with advanced non-squamous NSCLC: data of subgroup analyses from MO19390 (SAiL) study. Clin Transl Oncol. 2014;16(5):463–468. doi:10.1007/s12094-013-1102-524002945
   PubMed Web of Science ®Google Scholar
• Grandinetti CA, Goldspiel BR. Sorafenib and sunitinib: novel targeted therapies for renal cell cancer. Pharmacotherapy. 2007;27(8):1125–1144. doi:10.1592/phco.27.8.112517655513
   PubMed Web of Science ®Google Scholar
• Mross K, Frost A, Steinbild S, et al. A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors. Clin Cancer Res. 2012;18(9):2658–2667. doi:10.1158/1078-0432.CCR-11-190022421192
   PubMed Web of Science ®Google Scholar
• Sartore-Bianchi A, Zeppellini A, Amatu A, Ricotta R, Bencardino K, Siena S. Regorafenib in metastatic colorectal cancer. Expert Rev Anticancer Ther. 2014;14(3):255–265. doi:10.1586/14737140.2014.89488724559322
   PubMed Web of Science ®Google Scholar
• Keating GM, Santoro A. Sorafenib: a review of its use in advanced hepatocellular carcinoma. Drugs. 2009;69(2):223–240. doi:10.2165/00003495-200969020-0000619228077
   PubMed Web of Science ®Google Scholar
• van Geel RM, Beijnen JH, Schellens JH. Concise drug review: pazopanib and axitinib. Oncologist. 2012;17(8):1081–1089. doi:10.1634/theoncologist.2012-005522733795
   PubMed Web of Science ®Google Scholar
• Nosov DA, Esteves B, Lipatov ON, et al. Antitumor activity and safety of tivozanib (AV-951) in a phase II randomized discontinuation trial in patients with renal cell carcinoma. J Clin Oncol. 2012;30(14):1678–1685. doi:10.1200/JCO.2011.35.352422493422
   PubMed Web of Science ®Google Scholar
• Rugo HS, Herbst RS, Liu G, et al. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol. 2005;23(24):5474–5483. doi:10.1200/JCO.2005.04.19216027439
   PubMed Web of Science ®Google Scholar
• Liang S, Xu Y, Tan F, Ding L, Ma Y, Wang M. Efficacy of icotinib in advanced lung squamous cell carcinoma. Cancer Med. 2018. doi:10.1002/cam4.1736
   Web of Science ®Google Scholar
• Bao SS, Wen J, Zheng X, et al. Evaluation of the inhibition effects of apatinib on human and rat cytochrome P450. Toxicol Lett. 2018. doi:10.1016/j.toxlet.2018.08.010
   Web of Science ®Google Scholar
• Liu S, Wei H, Gong X, et al. LC-MS/MS method for simultaneous determination of famitinib and its major metabolites in human plasma. Bioanalysis. 2018;10(11):791–801. doi:10.4155/bio-2017-025829863414
   PubMed Web of Science ®Google Scholar
• Jiang JF, Chen XY, Zhong DF. Metabolic research of domestically developed small molecule tyrosine kinase inhibitors. Yao Xue Xue Bao. 2016;51(2):248–256.29856578
   PubMedGoogle Scholar
• Silva-Oliveira RJ, Silva VA, Martinho O, et al. Cytotoxicity of allitinib, an irreversible anti-EGFR agent, in a large panel of human cancer-derived cell lines: KRAS mutation status as a predictive biomarker. Cell Oncol (Dordr). 2016;39(3):253–263. doi:10.1007/s13402-016-0270-z26920031
   PubMed Web of Science ®Google Scholar
• Li J, Qin S, Xu RH, et al. Effect of fruquintinib vs placebo on overall survival in patients with previously treated metastatic colorectal cancer: the FRESCO randomized clinical trial. Jama. 2018;319(24):2486–2496. doi:10.1001/jama.2018.785529946728
   PubMed Web of Science ®Google Scholar
• Zhang L, Fan C, Guo Z, et al. Discovery of a potent dual EGFR/HER-2 inhibitor L-2 (selatinib) for the treatment of cancer. Eur J Med Chem. 2013;69:833–841. doi:10.1016/j.ejmech.2013.09.03224121234
   PubMed Web of Science ®Google Scholar
• Zhou S, Shao F, Xu Z, et al. A phase I study to investigate the metabolism, excretion, and pharmacokinetics of [(14)C]fruquintinib, a novel oral selective VEGFR inhibitor, in healthy Chinese male volunteers. Cancer Chemother Pharmacol. 2017;80(3):563–573. doi:10.1007/s00280-017-3394-628730290
   PubMed Web of Science ®Google Scholar
• Cassidy S, Syed BA. Colorectal cancer drugs market. Nat Rev Drug Discov. 2017;16(8):525–526. doi:10.1038/nrd.2017.5928529321
   PubMed Web of Science ®Google Scholar
• Ren Y, Sun Q, Long J, et al. Evaluation of fruquintinib, a potent and selective oral VEGFR inhibitor, in combination with targeted therapies or immune checkpoint inhibitors in preclinical tumor models. Cancer Research 2017;77(13):19106–14404.
   Google Scholar
• Burki TK. Fruquintinib for previously treated metastatic colorectal cancer. Lancet Oncol. 2018;19(8):e388.
   Google Scholar
• Gu Y, Wang J, Li K, et al. Preclinical pharmacokinetics and disposition of a novel selective VEGFR inhibitor fruquintinib (HMPL-013) and the prediction of its human pharmacokinetics. Cancer Chemother Pharmacol. 2014;74(1):95–115. doi:10.1007/s00280-014-2471-324817647
   PubMed Web of Science ®Google Scholar
• Health UDo, Human services F, Drug Administration CfDE, Research CfVm. Guidance for industry, bioanalytical method validation. Fed Regist. 2001;66(4):206–207.
   Google Scholar
• Yun C, Ding L, Leng Y, Zhu H, Wen A, Yang L. Determination of ipriflavone in human plasma by LC-MS and its application in a pharmacokinetic study. Biomed Chromatogr. 2012;26(1):123–128. doi:10.1002/bmc.164121594876
   PubMed Web of Science ®Google Scholar
• Yun C, Dashwood WM, Kwong LN, et al. Accurate quantification of PGE2 in the polyposis in rat colon (Pirc) model by surrogate analyte-based UPLC-MS/MS. J Pharm Biomed Anal. 2018;148:42–50. doi:10.1016/j.jpba.2017.07.02528957718
   PubMed Web of Science ®Google Scholar
• Yun C, Yin T, Shatzer K, et al. Determination of 7alpha-OH cholesterol by LC-MS/MS: application in assessing the activity of CYP7A1 in cholestatic minipigs. J Chromatogr B Analyt Technol Biomed Life Sci. 2016;1025:76–82. doi:10.1016/j.jchromb.2016.05.005
   PubMed Web of Science ®Google Scholar
• Xu RA, Lin Q, Qiu X, et al. UPLC-MS/MS method for the simultaneous determination of imatinib, voriconazole and their metabolites concentrations in rat plasma. J Pharm Biomed Anal. 2019;166:6–12. doi:10.1016/j.jpba.2018.12.03630594035
   PubMed Web of Science ®Google Scholar